The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosisLennart Lenk, Denis M. Schewe, Dorothee Winterberg et al.|Blood|2024Cited by 20
Abstract 2957: CD127 is expressed by acute lymphoblastic leukemias and is efficiently targeted by the IL7R-antagonist OSE-127 through macrophage-mediated antibody dependent phagocytosisIrène Baccelli, Nicolas Poirier, Lennart Lenk et al.|Cancer Research|2023Cited by 1
The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of ActionLennart Lenk, Denis M. Schewe, Irène Baccelli et al.|Blood|2022Cited by 0